• Je něco špatně v tomto záznamu ?

Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial

BI. Rini, MB. Atkins, ER. Plimack, D. Soulières, RS. McDermott, J. Bedke, S. Tartas, B. Alekseev, B. Melichar, Y. Shparyk, C. Kondoh, P. Langiewicz, LA. Wood, H. Hammers, CG. Silber, B. Haber, E. Jensen, M. Chen, T. Powles

. 2022 ; 5 (2) : 225-234. [pub] 20210706

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22018960

BACKGROUND: Pembrolizumab plus axitinib improved efficacy over sunitinib in treatment-naive advanced renal cell carcinoma in the KEYNOTE-426 (NCT02853331) study. However, a relatively high incidence of grade 3/4 aminotransferase elevations was observed. OBJECTIVE: To further characterize treatment-emergent aminotransferase elevations in patients treated with pembrolizumab-axitinib. DESIGN, SETTING, AND PARTICIPANTS: Patients enrolled in KEYNOTE-426 were included in this study. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Three Standardized MedDRA Queries for potential hepatic disorders were used to identify patients for the hepatic event analysis subpopulation (HEAS). Alanine aminotransferase events were characterized for time to onset, time to recovery, corticosteroid use, and rechallenge with study treatment(s). RESULTS AND LIMITATIONS: The HEAS comprised 189/429 (44%) pembrolizumab-axitinib patients and 128/425 (30%) sunitinib patients. Grade 3/4 hepatic adverse events were more common in the combination arm: 22% (94/429) versus 7% (29/425); 3% (13/429) discontinued the combination due to hepatic adverse events. In the pembrolizumab-axitinib arm, 125/426 patients (29%) had alanine aminotransferase (ALT) ≥3× upper limit of normal (ULN), with median time to onset of 84 d (range, 7-840 d). Among patients with ALT ≥3× ULN, 120/125 (96%) recovered to <3× ULN following study treatment interruption/discontinuation, with a median time to recovery of 15 d (3-176 d): 68/120 (57%) received corticosteroids. One hundred patients were rechallenged with one or both study treatment(s): 45/100 (45%) had ALT ≥3× ULN recurrence, and all 45 recovered to ALT <3× ULN following study treatment interruption/discontinuation. No fatal hepatic events occurred. CONCLUSIONS: A higher incidence of grade 3/4 aminotransferase elevations occurs with pembrolizumab-axitinib. These events should be carefully evaluated and managed with prompt study treatment interruption or discontinuation, with or without corticosteroid treatment. The decision to rechallenge with one or both drugs should be based on severity of event and thorough causality assessment. PATIENT SUMMARY: Renal cell carcinoma patients receiving pembrolizumab-axitinib are at a higher risk of liver enzyme elevations, which could be reversed with appropriate management.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22018960
003      
CZ-PrNML
005      
20220804135222.0
007      
ta
008      
220720s2022 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.euo.2021.05.007 $2 doi
035    __
$a (PubMed)34244116
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Rini, Brian I $u Vanderbilt University Medical Center, Nashville, TN, USA. Electronic address: brian.rini@vumc.edu
245    10
$a Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial / $c BI. Rini, MB. Atkins, ER. Plimack, D. Soulières, RS. McDermott, J. Bedke, S. Tartas, B. Alekseev, B. Melichar, Y. Shparyk, C. Kondoh, P. Langiewicz, LA. Wood, H. Hammers, CG. Silber, B. Haber, E. Jensen, M. Chen, T. Powles
520    9_
$a BACKGROUND: Pembrolizumab plus axitinib improved efficacy over sunitinib in treatment-naive advanced renal cell carcinoma in the KEYNOTE-426 (NCT02853331) study. However, a relatively high incidence of grade 3/4 aminotransferase elevations was observed. OBJECTIVE: To further characterize treatment-emergent aminotransferase elevations in patients treated with pembrolizumab-axitinib. DESIGN, SETTING, AND PARTICIPANTS: Patients enrolled in KEYNOTE-426 were included in this study. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Three Standardized MedDRA Queries for potential hepatic disorders were used to identify patients for the hepatic event analysis subpopulation (HEAS). Alanine aminotransferase events were characterized for time to onset, time to recovery, corticosteroid use, and rechallenge with study treatment(s). RESULTS AND LIMITATIONS: The HEAS comprised 189/429 (44%) pembrolizumab-axitinib patients and 128/425 (30%) sunitinib patients. Grade 3/4 hepatic adverse events were more common in the combination arm: 22% (94/429) versus 7% (29/425); 3% (13/429) discontinued the combination due to hepatic adverse events. In the pembrolizumab-axitinib arm, 125/426 patients (29%) had alanine aminotransferase (ALT) ≥3× upper limit of normal (ULN), with median time to onset of 84 d (range, 7-840 d). Among patients with ALT ≥3× ULN, 120/125 (96%) recovered to <3× ULN following study treatment interruption/discontinuation, with a median time to recovery of 15 d (3-176 d): 68/120 (57%) received corticosteroids. One hundred patients were rechallenged with one or both study treatment(s): 45/100 (45%) had ALT ≥3× ULN recurrence, and all 45 recovered to ALT <3× ULN following study treatment interruption/discontinuation. No fatal hepatic events occurred. CONCLUSIONS: A higher incidence of grade 3/4 aminotransferase elevations occurs with pembrolizumab-axitinib. These events should be carefully evaluated and managed with prompt study treatment interruption or discontinuation, with or without corticosteroid treatment. The decision to rechallenge with one or both drugs should be based on severity of event and thorough causality assessment. PATIENT SUMMARY: Renal cell carcinoma patients receiving pembrolizumab-axitinib are at a higher risk of liver enzyme elevations, which could be reversed with appropriate management.
650    _2
$a alanintransaminasa $x terapeutické užití $7 D000410
650    _2
$a humanizované monoklonální protilátky $7 D061067
650    _2
$a axitinib $x terapeutické užití $7 D000077784
650    12
$a karcinom z renálních buněk $x farmakoterapie $x patologie $7 D002292
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    12
$a nádory ledvin $x farmakoterapie $x patologie $7 D007680
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a sunitinib $x škodlivé účinky $7 D000077210
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Atkins, Michael B $u Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA
700    1_
$a Plimack, Elizabeth R $u Fox Chase Cancer Center, Philadelphia, PA, USA
700    1_
$a Soulières, Denis $u Centre Hospitalier de l'Universite de Montréal, Montréal, QC, Canada
700    1_
$a McDermott, Raymond S $u Adelaide and Meath Hospital and University College Dublin, Dublin, Ireland
700    1_
$a Bedke, Jens $u Eberhard Karls University of Tübingen, Tübingen, Germany
700    1_
$a Tartas, Sophie $u Centre Hospitalier Lyon-Sud, Pierre-Bénite, France
700    1_
$a Alekseev, Boris $u Federal Medical Research Center n.a. P.A. Hertsen, Moscow, Russia
700    1_
$a Melichar, Bohuslav $u Lekarska fakulta Univerzity Palackeho a Fakultni nemocnice Olomouc, Czech Republic
700    1_
$a Shparyk, Yaroslav $u Lviv State Oncology Regional Treatment and Diagnostic Center, Lviv, Ukraine
700    1_
$a Kondoh, Chihiro $u Toranomon Hospital, Tokyo, Japan
700    1_
$a Langiewicz, Przemyslaw $u Wojskowy Instytut Medyczny Centralny Szpital Medyczny MON, Warsaw, Poland
700    1_
$a Wood, Lori A $u Queen Elizabeth II Health Sciences Center, Halifax, NS, Canada
700    1_
$a Hammers, Hans $u University of Texas Southwestern Medical Center, Dallas, TX, USA
700    1_
$a Silber, Cynthia G $u Merck & Co., Inc., Kenilworth, NJ, USA
700    1_
$a Haber, Barbara $u Merck & Co., Inc., Kenilworth, NJ, USA
700    1_
$a Jensen, Erin $u Merck & Co., Inc., Kenilworth, NJ, USA
700    1_
$a Chen, Mei $u Merck & Co., Inc., Kenilworth, NJ, USA
700    1_
$a Powles, Thomas $u Barts Health and the Royal Free NHS Trusts, Barts Cancer Institute, and Queen Mary University of London, London, UK
773    0_
$w MED00205913 $t European urology oncology $x 2588-9311 $g Roč. 5, č. 2 (2022), s. 225-234
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34244116 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804135216 $b ABA008
999    __
$a ok $b bmc $g 1822519 $s 1170203
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 5 $c 2 $d 225-234 $e 20210706 $i 2588-9311 $m European urology oncology $n Eur Urol Oncol $x MED00205913
LZP    __
$a Pubmed-20220720

Najít záznam

Citační ukazatele

Možnosti archivace